التفاصيل البيبلوغرافية
| العنوان: |
Rifabutin-Based Triple Therapy (RHB-105) for Eradication: A Double-Blind, Randomized, Controlled Trial. |
| المؤلفون: |
Graham, David Y., Canaan, Yamil, Maher, James, Wiener, Gregory, Hulten, Kristina G., Kalfus, Ira N. |
| المصدر: |
Annals of Internal Medicine; 6/16/2020, Vol. 172 Issue 12, p795-802, 8p, 9 Charts |
| مصطلحات موضوعية: |
HELICOBACTER pylori infections, HELICOBACTER pylori, DRUG resistance in microorganisms, DRUG resistance in bacteria, CYTOCHROME P-450, ANTIBIOTICS, COMBINATION drug therapy, ANTI-infective agents, PROTON pump inhibitors, RANDOMIZED controlled trials, OMEPRAZOLE, BLIND experiment, STATISTICAL sampling, AMOXICILLIN, HELICOBACTER diseases |
| مصطلحات جغرافية: |
UNITED States |
| مستخلص: |
Background: Although consensus supports eradication of Helicobacter pylori infections, antimicrobial resistance has substantially reduced eradication rates with most current therapies.Objective: To assess the effectiveness of a novel rifabutin-based therapy (RHB-105) for H pylori eradication.Design: Phase 3, double-blind trial (ERADICATE Hp2). (ClinicalTrials.gov: NCT03198507).Setting: 55 clinical research sites in the United States.Participants: 455 treatment-naive adults with epigastric discomfort and confirmed H pylori infection.Intervention: RHB-105 (amoxicillin, 3 g; omeprazole, 120 mg; and rifabutin, 150 mg) versus active comparator (amoxicillin, 3 g, and omeprazole, 120 mg), given as 4 capsules every 8 hours for 14 days.Measurements: Between-group difference for H pylori eradication rate, demonstrated by 13C urea breath test 4 weeks after treatment, analyzed by using the χ2 test.Results: In the intention-to-treat population, the eradication rate was higher with RHB-105 than with the active comparator (228 vs. 227 patients, respectively; 83.8% [95% CI, 78.4% to 88.0%] vs. 57.7% [95% CI, 51.2% to 64.0%]; P < 0.001). Eradication rates were unaffected by resistance to clarithromycin or metronidazole. No rifabutin resistance was detected. The most commonly reported adverse events (incidence ≥5%) were diarrhea (10.1% with RHB-105 vs. 7.9% with active comparator), headache (7.5% vs. 7.0%), and nausea (4.8% vs. 5.3%).Limitation: Persons of Asian descent were excluded because of their higher prevalence of poor cytochrome P450 2C19 metabolizers.Conclusion: These findings suggest potential for RHB-105 as first-line empirical H pylori therapy, addressing an unmet need in the current environment of increasing antibiotic resistance.Primary Funding Source: RedHill Biopharma Ltd. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Internal Medicine is the property of American College of Physicians and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |